Prevalence of vulvar pain in an urban, minority population. Lavy RJ, Hynan LS, Haley RW J Reprod Med. 2007 Jan;52(1):59-62 OBJECTIVE: To determine the prevalence of vulvar pain in a large, urban, minority population. STUDY DESIGN: Women who presented to the University of Texas Southwestern Medical Center neighborhood clinic system for family planning services or gynecologic care were asked to complete a confidential questionnaire on the signs and symptoms of chronic vulvar pain. Responses were analyzed by ethnic group for the presence of vulvar pain. RESULTS: Three hundred twenty questionnaires were distributed, and 242 were completed,for a response rate of 75.6%. The population that completed the questionnaire (74% Hispanic, 20% African American, 5% Caucasian and 0.8% other) was similar in racial/ethnic distribution to the total population served in our health care system (66% Hispanic, 25% African American, 8% Caucasian and 1% other). Twenty-six (11%) women indicated they experienced vulvar pain. Sixteen women reported the start dates for the pain. Ten (63%) reported vulvar pain for more than 1 month. Of the 26 women reporting pain, the racial distribution was similar to that of our surveyed population (85% Hispanic, 11% African American, 4% Caucasian and 0% other). CONCLUSION: The prevalence of vulvar pain in this urban minority population was 11%. The prevalence of vulvar pain was similar among women of different racial/ethnic groups.
PURPOSE: In women symptoms of interstitial cystitis are difficult to distinguish from those of painful bladder syndrome and they appear to overlap with those of urinary tract infection, chronic urethral syndrome, overactive bladder, vulvodynia and endometriosis. This has led to difficulties in formulating a case definition for interstitial cystitis, and complications in the treatment and evaluation of its impact on the lives of women. We performed a systematic literature review to determine how best to distinguish interstitial cystitis from related conditions. MATERIALS AND METHODS: We performed comprehensive literature searches using the terms diagnosis, and each of interstitial cystitis, painful bladder syndrome, urinary tract infection, overactive bladder, chronic urethral syndrome, vulvodynia and endometriosis. RESULTS: Of 2,680 screened titles 604 articles were read in full. The most commonly reported interstitial cystitis symptoms were bladder/pelvic pain, urgency, frequency and nocturia. Interstitial cystitis and painful bladder syndrome share the same cluster of symptoms. Chronic urethral syndrome is an outdated term. Self-reports regarding symptoms and effective antibiotic use can distinguish recurrent urinary tract infections from interstitial cystitis in some but not all women. Urine cultures may also be necessary. Pain distinguishes interstitial cystitis from overactive bladder and vulvar pain may distinguish vulvodynia from interstitial cystitis. Dysmenorrhea distinguishes endometriosis from interstitial cystitis, although many women have endometriosis plus interstitial cystitis. CONCLUSIONS: In terms of symptoms interstitial cystitis and painful bladder syndrome may be the same entity. Recurrent urinary tract infections may be distinguished from interstitial cystitis and painful bladder syndrome via a combination of self-report and urine culture information. Interstitial cystitis and painful bladder syndrome may be distinguished from overactive bladder, vulvodynia and endometriosis, although identifying interstitial cystitis and painful bladder syndrome in women with more than 1 of these diseases may be difficult. Provoked vestibulodynia is a common cause of superficial dyspareunia in young women. Recent evidence has pointed out the importance of studying endogenous pain modulation in these women. An impairment of diffuse noxious inhibitory controls (DNIC) has been suggested in chronic pain conditions with a female predominance such as fibromyalgia and temporomandibular disorder. Our aim was to examine whether patients with provoked vestibulodynia and healthy women with or without combined oral contraceptives (COC) display a DNIC response to cold noxious stimulation. Twenty patients with provoked vestibulodynia not using COC, 20 healthy women on COC and 20 healthy women without COC were included and tested days 7-11 of their menstrual cycle. Pressure pain thresholds (PPTs) and pain ratings using VAS were measured on the arm and leg before and during a cold pressor test. A sociomedical questionnaire, the Hospital and Anxiety Depression Scale and the Short Form-36 were completed. The majority of the subjects in all three study groups significantly increased their PPTs during cold noxious stimulation indicating a DNIC response. The patients displayed lower PPTs compared to the healthy women. Depression, anxiety and bodily pain were more often reported by the patients. No differences related to the intake of COC were observed between the healthy women. In conclusion, women with provoked vestibulodynia as well as healthy women irrespective of COC status display a DNIC response indicating an endogenous pain inhibition. However, the results imply a systemic hypersensitivity in women with vestibulodynia with low general pain thresholds as compared to healthy women.
Evidence of diffuse noxious inhibitory controls (DNIC

Value of colposcopy in the diagnosis of candidiasis in patients with vulvodynia.
Pagano R J Reprod Med. 2007 Jan;52(1):31-4 OBJECTIVE: To evaluate the value of colposcopy in the diagnosis of chronic vulvar candidiasis in patients presenting with vulvodynia. STUDY DESIGN: A prospective study of 460 patients presenting with vulvodynia over a 24-month period was undertaken. All patients underwent colposcopy of the vulva, which was regarded as positive if acetowhite lesions with central clearing with or without petechiae were present. Vulvar skin scrapings were taken for Candida culture on all patients. Those patients with positive colposcopic findings were treated with long-term oral antimycotic therapy irrespective of laboratory findings. RESULTS: Patients with positive colposcopic findings and positive cultures had a 93% rate of improvement in symptoms. Those with positive colposcopic findings and negative cultures also had a 60% rate of improvement. Thus, the overall improvement rate in patients with positive colposcopic findings (irrespective of culture results) was 76%. When colposcopy findings were negative, Candida cultures were also negative in 92% of patients. CONCLUSION: Colposcopy of the vulva can be a valuable triage tool in the assessment of patients with vulvodynia by detecting changes that are highly suspicious for the presence of chronic vulvar candidiasis. STUDY DESIGN: Retrospective review and follow-up mail survey of women with vestibulodynia who underwent laser treatment. Demographics, number of laser treatments and symptom severity prior to laser treatment (100-mm visual analog scale) were obtained from the medical record. The survey included questions regarding current sexual pain, sexual quality of life and satisfaction with treatment. RESULTS: Of41 treated women, 37 women were located and agreed to participate. The mean number of laser sessions was 2.81 (range, 1-8). The mean age was 32.9 years and mean follow-up, 2.8. Following laser treatment, most (24 of 37, 68%) subjects reported less pain with sexual intercourse. One subject reported more pain, while 29% (11 of 37) reported no change. Sixty percent (21 of 37) reported their sex lives to be more satisfying/pleasurable following laser treatment. Thirteen women (13 of 37, 35%) underwent vestibulectomy following laser therapy, and 2 subjects were treated with a laser after failed vestibulectomy. CONCLUSION: Most women with vestibulodynia treated with a KTP-Nd:YAG laser achieve a reduction in sexual pain and improved sexual satisfaction without excisional therapy. Clinically, botulinum toxin A blocks the cholinergic innervation of the target tissue. Recently, it has been proved effective not only at a neuromuscular junction but also within parasympathetic or sympathetic neural synapses. Seven women with pain on genitalia that could not be controlled with conventional pain managements were enrolled in this study. Twenty to 40 U of botulinum toxin A were used in each injection. Injection sites were the vestibule, levator ani muscle or the perineal body. Repeat injections were administered every 2 weeks if the patient's symptoms had not fully subsided. In all patients, pain had disappeared with botulinum toxin A injections. Five patients needed to be injected twice; the other two patients needed only one injection. We did not observe complications related to botulinum toxin A injections, such as pain, hemorrhage, infection, muscle paralysis or other complications. The subjective pain score improved from 8.3 to 1.4, and no one has experienced a recurrence (the follow-up period was four to 24 months, with a mean follow-up of 11.6 months). Botulinum toxin A is effective in blocking nociception. Even though further investigation and well-controlled study will be necessary, we suggest that the botulinum toxin therapy would be useful and safe in managing vulvodynia of muscular or neuroinflammatory origins. It queried clinicians' demographics, physician/clinician referral patterns, assessment/ treatment modalities and length of care. RESULTS: Nearly two-thirds reported >11 years of physical therapy experience, with 42% treating women with vulvodynia for > 6 years. Most referrals were from obstetrician/gynecologists. Assessment modalities used by > 70% included detailed history; assessment of posture, tension in the pelvic floor, pelvic girdle, associated pelvic structures and bowel/bladder function; digital sEMG/pEMG testing of the pelvic floor; hip, sacroiliac joints and spine mobility; strength testing of abdominals and lower extremities; and voiding diaries. Nearly 70% utilized exercise for the pelvic girdle and pelvic floor; soft tissue mobilization/myofascial release of the pelvic girdle, pelvic floor and associated structures; joint mobilization/manipulation; bowel/bladder retraining and help with contact irritants, dietary changes and sexual function. Typical care is 60-minute weekly sessions for 7-15 weeks. CONCLUSION: Sixty-three percent of physical therapists in the U.S. treating women with LPV have > 11 years of experience, with almost half treating women for > 6 years. Obstetrician/gynecologists are the largest referral source. Three quarters agree on 14 assessment tools, while more than two thirds agree on 11 treatments. Women are treated weekly for 1 hour, for 7-15 weeks.
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A qualitative study of women with vulvodynia: I. The journey into treatment. Buchan A, Munday P, Ravenhill G, Wiggs A, Brooks F J Reprod Med. 2007 Jan;52(1):15-8 OBJECTIVE: To evaluate women's experiences of accessing help and treatment for vulvodynia. STUDY DESIGN: Women who had participated in a vulvar pain management program were evaluated in a retrospective, qualitative, in-depth interview study. RESULTS: The women described their distressing symptoms of vulvodynia and their previous experiences of seeking help. The women thought that the delay to diagnosis contributed to the severity of their symptoms and that achieving a diagnosis was the first step on a path toward the acceptance of a chronic condition and a commitment to a management program. CONCLUSION: Vulvodynia is poorly recognized, and the delay to diagnosis adversely affects patients, exacerbating the severity of their symptoms.
A qualitative study of women with vulvodynia: II. Response to a multidisciplinary approach to management. Munday P, Buchan A, Ravenhill G, Wiggs A, Brooks F J Reprod Med. 2007 Jan;52(1):19-22 OBJECTIVE: To evaluate the response of a group of women with vulvodynia who were participating in an integrated, multidisciplinary management program comprising medical evaluation and treatment, psychotherapy, physiotherapy and dietary advice. STUDY DESIGN: Retrospective, qualitative, in-depth interview study. RESULTS: Twenty-seven of 29 women reported a significant benefit, and 9 who had completed the program were pain free. All women appreciated the integrated approach, and even those who were not completely pain free found that they were able to manage their condition satisfactorily. CONCLUSION: Further evaluation of this program is warranted to assess whether it would be helpful for other women with this problem. OBJECTIVE: To assess the psychosexual profile of vulvodynia patients, focusing on the age at onset and age distribution, and to analyze the impact of vulvodynia on the emotional, social and sexual well-being of this patient population. STUDY DESIGN: A retrospective review was performed of patient files consisting of questionnaires, psychometric tests, sexual history, electromyographic assessments and clinical notes. RESULTS: The highest prevalence of vulvodynia in this clinical sample occurred before the age of 25 years; 75% of the 744 patients were under the age of 34. A comparison of primary and secondary vulvodynia patients showed the average age at symptom onset to be 19.1 years for primary cases and 25.0 years for secondary cases. There were significant differences in duration of symptoms, age at first sexual intercourse and number of sexual partners, even when controlling for age (p < 0.001). Marriage provided an effective buffer against depression and anxiety. CONCLUSION: Vulvodynia can have an early onset and affect social relationships. Given the psychologic distress associated with vulvodynia, early diagnosis and treatment of the medical aspects are essential, as is focusing on the psychosexual implications of this pain syndrome.
